Issues and progress with protein kinase inhibitors for cancer treatment

被引：424

作者：

Dancey, J

Sausville, EA

机构：

[1] NCI, Div Canc Treatment & Diag, Canc Therapy Evaluat Program, Investigat Drug Branch, Rockville, MD 20852 USA

[2] NCI, Div Canc Treatment & Diag, Dev Therapeut Program, Rockville, MD 20852 USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2003年 / 2卷 / 04期

关键词：

D O I：

10.1038/nrd1066

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Identification of the key roles of protein kinases in cancer has led to extensive efforts to develop kinase inhibitors for the treatment of a wide range of cancers, and more than 30 such agents are now in clinical trials. Here, we consider the crucial issues in the development of kinase inhibitors for cancer, and discuss strategies to address the challenges raised by these issues in the light of preclinical and clinical experiences so far.

引用

页码：296 / 313

页数：18

共 150 条

[1] Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition
Albanell, J
Rojo, F
Averbuch, S
Feyereislova, A
Mascaro, JM
Herbst, R
LoRusso, P
Rischin, D
Sauleda, S
Gee, J
Nicholson, RI
Baselga, J
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) : 110 - 124
[2] Atkins M.B., 2002, P AN M AM SOC CLIN, V21, P36
[3] Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
Baselga, J
Pfister, D
Cooper, MR
Cohen, R
Burtness, B
Bos, M
D'Andrea, G
Seidman, A
Norton, L
Gunnett, K
Falcey, J
Anderson, V
Waksal, H
Mendelsohn, J
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (04) : 904 - 914
[4] Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types
Baselga, J
Rischin, D
Ranson, M
Calvert, H
Raymond, E
Kieback, DG
Kaye, SB
Gianni, L
Harris, A
Bjork, T
Averbuch, SD
Feyereislova, A
Swaisland, H
Rojo, F
Albanell, J
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) : 4292 - 4302
[5] BASELGA J, 2002, P AN M AM SOC CLIN, V21, P900
[6] Influence of unrecognized molecular heterogeneity on randomized clinical trials
Betensky, RA
Louis, DN
Cairncross, JG
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (10) : 2495 - 2499
[7] Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses
Bhattacharjee, A
Richards, WG
Staunton, J
Li, C
Monti, S
Vasa, P
Ladd, C
Beheshti, J
Bueno, R
Gillette, M
Loda, M
Weber, G
Mark, EJ
Lander, ES
Wong, W
Johnson, BE
Golub, TR
Sugarbaker, DJ
Meyerson, M
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (24) : 13790 - 13795
[8] Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family
Bishop, PC
Myers, T
Robey, R
Fry, DW
Liu, ET
Blagosklonny, MV
Bates, SE
[J]. ONCOGENE, 2002, 21 (01) : 119 - 127
[9] Oncogenic kinase signalling
Blume-Jensen, P
Hunter, T
[J]. NATURE, 2001, 411 (6835) : 355 - 365
[10] p38 and Chk1 kinases:: different conductors for the G2/M checkpoint symphony
Bulavin, DV
Amundson, SA
Fornace, AJ
[J]. CURRENT OPINION IN GENETICS & DEVELOPMENT, 2002, 12 (01) : 92 - 97

← 1 2 3 4 5 6 7 8 9 10 →